At Parabilis we are dedicated to creating medicines with life-changing impact, not just for patients but for the countless other individuals who care about them.
Our patient commitment
We are developing cutting-edge treatments tailored to address the most pressing health challenges of people with cancer. We know we must deliver our medicines as rapidly and as thoughtfully as possible, and we single-mindedly pursue only those medicines that can address true patient needs. Through our relationships with patients, advocacy groups, and physicians, we seek to understand the lived experience of patients. We maintain a global perspective, knowing that cancer’s devastating impact doesn’t abide by any geographic bounds.
We are committed to making our novel therapeutics accessible by generating sound data and eliminating barriers to care, thereby maximizing access at launch. We aim to provide support to patients throughout their treatment journey, to ensure that our life-changing therapies reach all patients who can benefit.
“My purpose is to bring new hope for patients. This is what drives me each day to build, evaluate and help to validate new treatment for patients.”
Fawzi Benzaghou, M.D. Chief Medical Officer
Clinical trials
Phase 1/2 trial of zolucatetide
Now EnrollingWe are currently evaluating zolucatetide (previously known as FOG-001) in a first-in-human Phase 1/2 clinical trial. This multicenter, open-label trial will aim to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of zolucatetide in patients with locally advanced or metastatic solid tumors. Learn more about zolucatetide here.
For more information call (857) 259-6305
or email us at [email protected]
Expanded access statement
Parabilis Medicines’ drug development is focused on conducting clinical trials to fully answer questions about the potential risks and benefits of our investigational products, which if successful will allow us to seek regulatory approval. We believe that participation in our clinical trials is the best way to access our investigational products prior to their approval and the best way to expedite access to our drugs for appropriate patients. At this time, Parabilis Medicines does not provide investigational products through Investigator Sponsored Trials or an Expanded Access Program.
More information about our clinical trials can be found HERE. Please contact us with any questions at [email protected].
We appreciate the ongoing contributions of the patients who participate in our clinical trials and the scientific community in driving medical advancements and remain dedicated to fostering innovation.
